Holen Sie sich die Stockscreener-App
2.98
18.73%
0.47
Schlusskurs vom Vortag:
$2.51
Offen:
$2.76
24-Stunden-Volumen:
73,475
Relative Volume:
0.58
Marktkapitalisierung:
$211.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-2.97M
KGV:
-3.0162
EPS:
-0.988
Netto-Cashflow:
$-1.18M
1W Leistung:
+29.85%
1M Leistung:
+40.57%
6M Leistung:
-69.72%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.415
$3.2399
1-Wochen-Bereich:
$2.1701
$3.2399
52-Wochen-Spanne:
$1.70
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
2.98 | 184.16M | 0 | -2.97M | -1.18M | -0.988 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Yd Bio Ltd Aktie (YDES) Neueste Nachrichten
YD Bio Ord Shs (YDES) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
YD Bio launches nutrition products via physician partnership model By Investing.com - Investing.com South Africa
YD Bio launches nutrition products via physician partnership model - Investing.com
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute - Yahoo Finance
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research - Yahoo Finance
Keratoconus Study Ranks Molecules for Future Corneal Therapy Research - Stock Titan
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada - The Manila Times
YD Bio launches pilot for cancer testing in British Columbia By Investing.com - Investing.com Canada
Five Cancer Types Targeted in YD Bio's Cross-Border Pilot - Stock Titan
Y.D. More group (TATT) reports 5.42% beneficial stake in TAT Technologies - Stock Titan
YD Bio Ord Shs (YDES) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
YD Bio launches pilot for cancer testing in British Columbia - Investing.com
YD Bio Ord Shs (YDES) Cash Flow - TradingKey
YDES|YD Bio Ord Shs|Price:2.350|Chg%:+0.110 - TradingKey
YD Bio Ord Shs (YDES) Balance Sheet - TradingKey
YDES|YD Bio Ord Shs|Price:2.300|Chg%:-0.020 - TradingKey
YD Bio Ord Shs (YDES) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
YD Bio Ord Shs (YDES) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
YD Bio Ord Shs (YDES) Institutional Confidence - TradingKey
YD Bio Ord Shs (YDES) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
YD Bio Ord Shs (YDES) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
YDES|YD Bio Ord Shs|Price:2.240|Chg%:+0.200 - TradingKey
YD Bio Ord Shs (YDES) Income Statement - TradingKey
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services - The Manila Times
30 Prospective Partners Explore Cancer Tests and Eye Care at Taiwan Expo - Stock Titan
Diabetic Macular Edema Pipeline 2026: MOA, ROA, FDA-Approved - openPR.com
Gapping stocks in Wednesday's session - ChartMill
Enterprise value to revenue forward of YD Bio Limited – NASDAQ:YDES - TradingView
PLPC Q1 2026 Earnings: EPS Surprises to the Upside, but Stock DeclinesAnnual Report - dars.gov.et
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Which stocks have an unusual volume on Tuesday? - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
YD Bio (YDESW) Stock Analysis Report | Financials & Insights - Benzinga España
YD Bio affiliate obtains lab licenses in Rhode Island, Pennsylvania - Investing.com
YD Bio affiliate obtains lab licenses in Rhode Island, Pennsylvania By Investing.com - Investing.com Canada
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations - Yahoo Finance
Yidu Tech Achieves Its First Full-Year Profit: FY2026 Net Profit Reaches RMB 78.8 Million, with Positive Operating Cash Flow in the Second Half - Yahoo Finance
RSU grant and exercise update for YD Bio (YDES) director Lu - Stock Titan
RSU grant and exercise for YD Bio (YDES) director Chang Kochi - Stock Titan
YD Bio Ltd (NASDAQ: YDES) Share Price, YDES Stock News, YDES Share Price & Updates - Kalkine
MegaGen and BIOLASE Invest Nearly $1 Million to Expand Manufacturing Infrastructure at Corona, California Facility - Yahoo Finance
Morning Market Movers: CUPR, BNC, ABSI, WEN See Big Swings - RTTNews
BRZHR Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
YD Bio Ord Shs (YDES) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
YD Bio Ord Shs (YDES) Valuation: PE, PB & Fair Value Analysis - TradingKey
Morning Market Movers: SLBT, SCLX, TDIC, CRE See Big Swings - RTTNews
FOCL Stock Price and Chart — NASDAQ:FOCL - TradingView
[EFFECT] YD Bio Ltd SEC Filing - Stock Titan
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - Yahoo Finance
Saga Communications (SGA) Drops 4.3%: Support Levels in Focus After Recent DeclineDescending Triangle - dars.gov.et
Finanzdaten der Yd Bio Ltd-Aktie (YDES)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):